Equillium

Equillium FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Equillium (EQ) as of Oct 11, 2026 is 101.77 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 236.90 % — a change of -57.04% (lower).

FCF Conversion

101.77 %

YoY

-57.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Equillium is 2025 101.77 % . FCF Conversion Rate (FCF/EBITDA) of Equillium was 2024 236.90 % . It decreases by -57.04% lower compared to the previous year.

The Equillium FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
57.06 USD
Jan 1, 2019
90.01 USD
Jan 1, 2020
83.40 USD
Jan 1, 2021
82.45 USD
Jan 1, 2022
14.44 USD
Jan 1, 2023
163.73 USD
Jan 1, 2024
236.90 USD
Jan 1, 2025
101.77 USD
The Equillium FCF Conversion history
YEARFCF ConversionYoY
101.77 %-57.04%
236.90 %+44.69%
163.73 %+1,034.17%
14.44 %-82.49%
82.45 %-1.14%
83.40 %-7.35%
90.01 %+57.74%
57.06 %+94.27%
29.37 %—
Access this data via the Eulerpool API

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

FCF Conversion Rate (FCF/EBITDA) of Equillium is 101.77 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Equillium changed from 236.90 % to 101.77 %, representing a -57.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Equillium since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Equillium with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Equillium

All Key Metrics — Equillium